Cell Therapy Services, Banc de Sang i Teixits, Barcelona, Spain.
Transfusion. 2019 Oct;59(10):3048-3050. doi: 10.1111/trf.15466. Epub 2019 Aug 2.
Cord blood (CB) is a medicinal product of human origin with unique cellular properties such as the presence of multipotent stem cells, naive immune cells, and fetal blood components. CB transplantation provides high rate of donor chimerism, and a good balance of graft-versus-host (GVH) and graft-versus-leukemia (GVL) effects. Use of CB for transplantation has decreased in recent years as haplo-identical stem cell transplants have achieved similar short-term clinical outcomes. For most patients, however, the optimal stem cell source remains unclear. CB inventories can be used as a starting material to develop new cellular medicines, and units with low cellular content can be converted to produce blood components like platelet-rich plasma and red blood cell (RBC) units for special indications.
脐带血(CB)是一种源自人体的药物,具有独特的细胞特性,如存在多能干细胞、幼稚免疫细胞和胎儿血液成分。CB 移植提供了高供者嵌合率,并具有良好的移植物抗宿主(GVH)和移植物抗白血病(GVL)效应的平衡。近年来,由于半相合干细胞移植已取得类似的短期临床结果,CB 移植的使用有所减少。然而,对于大多数患者而言,最佳的干细胞来源仍不清楚。CB 库存可用作开发新细胞药物的起始材料,并且可以将细胞含量低的单位转化为用于特殊适应症的富含血小板血浆和红细胞(RBC)单位等血液成分。